|1.||Hartmann, Rolf W: 10 articles (08/2013 - 12/2004)|
|2.||Njar, Vincent C O: 9 articles (05/2011 - 10/2004)|
|3.||Auchus, Richard J: 8 articles (04/2015 - 12/2003)|
|4.||Hu, Qingzhong: 8 articles (01/2014 - 08/2008)|
|5.||Attard, Gerhardt: 8 articles (08/2011 - 08/2008)|
|6.||de Bono, Johann S: 7 articles (04/2011 - 08/2008)|
|7.||Miller, Walter L: 6 articles (06/2015 - 06/2004)|
|8.||Qiao, Jie: 5 articles (02/2015 - 03/2010)|
|9.||Flück, Christa E: 5 articles (05/2014 - 08/2006)|
|10.||Tsai, Fuu-Jen: 5 articles (10/2005 - 07/2003)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/2011 - "Thus, total ablation of androgen production by potent CYP17 inhibitors may provide effective treatment of prostate cancer patients. "
03/01/1999 - "Thus total blockade of androgen production by CYP17 inhibitors may provide effective treatment of prostate cancer patients. "
02/15/2008 - "Using resources from the Flint Men's Health Study, a population-based case control study of African-American men aged 40-79, we evaluated the associations between selected single-nucleotide polymorphisms (SNPs) in the CYP17, CYP3A4, CYP19A1, SDR5A2, IGF1, and IGFBP3 genes and prostate cancer diagnosis in 473 men (131 prostate cancer cases and 342 disease-free controls). "
06/01/2014 - "This process produced a unique series of CYP17 lyase-selective inhibitors that included the oral agent 6 (VT-464), now in Phase 2 prostate cancer clinical trials. "
01/01/2013 - "Therefore, the aim of this study was to perform a meta-analysis to investigate the association between the CYP17 MspA1 polymorphism and the risk of prostate cancer. "
01/01/2015 - "The frequency of mutant allele A2 of CYP17 MspA1 gene polymorphism was higher among cancer (OR=5.13, 95% CI+3.10-8.51, p=0.0001), stone (OR=5.69, 95%CI=3.46-9.37, p=0.0001) and cancer+stone (OR=3.54, 95%CI=1.90-6.60, p=0.0001) when compared with the control group. "
01/01/2015 - "Pretreatment tumor nuclear AR overexpression (> 75%) and CYP17 (> 10%) expression were associated with benefit (p = 0.018). "
07/01/2014 - "In tumors, immunostaining of CYP21 was low, whereas staining of Cyp17 and CytB5, necessary for androgen synthesis, was present. "
01/01/2014 - "Genetics, structure, function, mode of actions and role in cancer development of CYP17."
02/20/2012 - "Homogeneous, intense nuclear expression of AR, combined with ≥ 10% CYP17 tumor expression, was correlated with longer time to treatment discontinuation (> 4 months) in 25 patients with tumor-infiltrated bone marrow samples. "
03/01/2001 - "All the compounds were also tested on 17 alpha-hydroxylase/C17,20-lyase (P450 17), an enzyme of therapeutic interest for the treatment of prostatic diseases. "
09/01/2013 - "Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases."
09/01/2013 - "5α-Reductase is primarily of interest in benign prostatic disease, though some role in the chemoprevention of prostatic carcinoma have been considered, whereas the 17α-hydroxylase/17,20-lyase (CYP17) enzyme is of interest in the treatment of malignant disease. "
|4.||Breast Neoplasms (Breast Cancer)
02/01/2014 - "The purpose of actual study was to analyze the associations of polymorphic loci CYP17/B1rs10556836, CYP1A 1rs1048943, CYP1A2rs762551, CYP19A1rs2470152 and CYP17A1rs743572 with risk of development of breast cancer in Russian residents of the Western-Siberian region of Russia. "
07/01/2010 - "A number of studies have been investigated the association between CYP17 T34C polymorphism and the risk of breast cancer; the results of these studies are inconsistent, however. "
07/01/2010 - "When all 35 studies were pooled into the meta-analysis, there was no evidence for significant association between CYP17 MspA1 polymorphism and breast cancer risk (for A1/A2 vs. A1/A1: OR = 1.00, 95% CI = 0.96-1.04; for A2/A2 vs. A1/A1: OR = 1.03, 95% CI = 0.97-1.08; for dominant model: OR = 1.01, 95% CI = 0.97-1.05; for recessive model: OR = 1.03, 95% CI = 0.98-1.08). "
04/01/2007 - "In conclusion, this study suggests that short menstrual cycles, age at first OC use and BRCA mutation status may need to be considered in studies exploring the relationships between CYP17 and risk factors for early onset breast cancer."
01/01/2007 - "This study evaluates the influence of genetic polymorphism of CYP17 on breast cancer susceptibility. "
|5.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
06/01/2012 - "Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage."
08/01/1998 - "These two mutations have contributed substantially to our understanding of the mechanisms by which 17alpha-hydroxylase and 17,20 lyase activities are regulated independently, and thus have contributed to the study of regulated 17,20 lyase activity in adrenarche, aging, and the polycystic ovary syndrome."
03/01/2012 - "The T→C polymorphism of CYP17 gene has been inconsistently associated with polycystic ovary syndrome (PCOS) risk. "
03/01/2012 - "Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis."
02/01/2005 - "We have investigated the involvement of the MAPK signaling pathway in increased androgen biosynthesis and CYP17 gene expression in women with polycystic ovary syndrome (PCOS). "
|1.||Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
|3.||Androgen Receptors (Androgen Receptor)
|5.||Cytochrome P-450 CYP1A1 (CYP1A1)
|7.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|9.||DNA (Deoxyribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)